FDA Clearance Tracker · K261336
Xpert Respiratory Panel
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 2026
Substantially Equivalent
Time to decision
155 days
Received Apr 23, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K261336
- Device name
- Xpert Respiratory Panel
- Applicant
- Cepheid
- Applicant location
- Sunnyvale, CA
- Received
- Apr 23, 2026
- Decided
- Sep 25, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3981
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QOF. The earliest in FDA's data is DEN200031, decided Mar 17, 2021.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K261336
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Cepheid
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262971 · Decided Oct 30, 2026 · 65 days after receipt
Device type: Multiplex Nucleic Acid Detection System For Biothreat Agents (QVR) · Laboratory Medicine & Pathology
K263333 · Decided Oct 22, 2026 · 30 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
K263120 · Decided Oct 2, 2026 · 28 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.